Nevertheless, European companies have found themselves in the sights of America’s president, who is irked by the fact that ...

HIMS posted stellar Q1 FY 2025; growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Click here to ...

How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created ...

Internationally, the scale is far smaller. There is not a single public company outside the US currently worth $1 trillion.

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Denmark’s exports will grow clearly less than expected earlier, partly due to the setbacks Novo Nordisk A/S is facing in the ...

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and ...